Drug intelligence / Profile preview

alemtuzumab + mitoxantrone + natalizumab + ocrelizumab + rituximab

Development stage: Unknown
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination of five different disease-modifying therapies used in the treatment of multiple sclerosis (MS). Alemtuzumab is a humanized monoclonal antibody that targets CD52, causing profound lymphocyte depletion followed by repopulation with a regulatory bias. Mitoxantrone is an antineoplastic agent. Natalizumab is a monoclonal antibody that inhibits leukocyte migration. Ocrelizumab targets CD20-positive B cells. Rituximab is an anti-CD20 monoclonal antibody that depletes B cells.

Targets

ITGA4 (Integrin alpha-4)CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)CD52 (CD52 Antigen)DNA

Beyond the preview

Go deeper on alemtuzumab + mitoxantrone + natalizumab + ocrelizumab + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alemtuzumab + mitoxantrone + natalizumab + ocrelizumab + rituximab.

Explore the full profile